

Progression Suppression and Retinal Regression in VEGF-resistant AMD

NCT07005323

Status	RECRUITING
Phase	Not Applicable
Sponsor	PharmaBio Corporation
Enrollment	10 participants

Key Eligibility Criteria

Inclusion (9)

- Patients aged between 50 and 85 years at the time of consent acquisition
- Patients diagnosed neovascular AMD in one or both eyes
- Patients with corrected letter vision in the subject eye of 20 letters or more (equivalent to decimal vision of 0.05) and less than 60 letters (equivalent to decimal vision of 0.32)
- Patients who apply to one or more of the followings:
- RPE defect site in the RPE tear includes the Fovea
- ... and 4 more (see full listing online)

Exclusion (18)

- Patients with fibrovascular pigment epithelial detachment (thickness 50 µm or more) in the subfoveal area in the subject eye.
- Patients with hard exudates in the subretinal or intraretinal area in the subject eye.
- Patients with eye infections
- Patients with a history of retinal vascular disease other than neovascular AMD, retinal degenerative disease, rhegmatogenous retinal detachment, macular hole, premacular membrane with retinal wall, uveitis, or other ocular inflammatory disease in the subject eye.
- Patients with optic nerve atrophy in the subject eye
- ... and 13 more (see full listing online)

Locations (1 total)

Yamaguchi University Hospital, Ube, Yamaguchi, Japan